(Q33391561)

26 July 2017

title

Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

metastatic colon cancer

1 reference

1 reference

Gyeong Hoon Kang

9

0 references

Yung-Jue Bang

10

object named as

Yung-Jue Bang

1 reference

26 July 2017

8

Seock-Ah Im

1 reference

26 July 2017

7

Do-Youn Oh

1 reference

26 July 2017

2

Sae-Won Han

1 reference

26 July 2017

11

Tae-You Kim

1 reference

26 July 2017

3

Hye Seon Ham

1 reference

26 July 2017

Junshik Hong

1

1 reference

26 July 2017

Tae-Yong Kim

4

1 reference

26 July 2017

In Sil Choi

5

1 reference

26 July 2017

Byung-Su Kim

6

1 reference

26 July 2017

publication date

24 August 2010

1 reference

Cancer Chemotherapy and Pharmacology

26 July 2017

published in

1 reference

26 July 2017

volume

67

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

1323-1331

1 reference

Nationwide cancer incidence in Korea, 2003-2005.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

The role of pharmacogenetics in cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1425-7

10.1007/S00280-010-1425-7

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1045875020

0 references

Fatcat ID

release_uv3jqai3fzecpaobvdpxjkizme

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uv3jqai3fzecpaobvdpxjkizme

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference